Drug Trial News

RSS

Clinical trial highlights efficacy of imlifidase for kidney transplant recipients

For kidney transplant recipients experiencing antibody-mediated rejection, the current standard of care involves removing donor-specific antibodies (DSAs) through plasmapheresis (PLEX)-;a procedure that removes antibodies from the plasma portion of the blood.

27 Oct 2024

Phase 3 trial assesses clazakizumab in kidney transplant recipients with caAMR

Chronic active antibody-mediated rejection (caAMR) is a common cause of allograft loss after transplantation, with no approved therapies. Clazakizumab, a monoclonal antibody that targets the inflammatory cytokine interleukin-6 (IL-6), stabilized kidney transplant recipients' kidney function in a phase 2 trial.

27 Oct 2024

Single treatment with CRISPR gene editing therapy offers hope for hereditary angioedema patients

A single treatment with, a CRISPR-Cas9 based gene editing therapy, is enough to replace the daily medication of patients with hereditary angioedema (HAE), a condition characterized by severe, painful and sudden onset of swelling, sometimes resulting in death.

25 Oct 2024

New drug TYRA-300 shows effectiveness in treating metastatic bladder cancer

Patients with advanced bladder cancer that had spread to other parts of the body (metastasized) have responded well in a phase I clinical trial of an investigational drug, TYRA-300.

24 Oct 2024

Targeted therapy and immunotherapy improve outcomes in rare thyroid cancer

Researchers from The University of Texas MD Anderson Cancer Center demonstrated that anti-PD-L1 immunotherapy in combination with mutation-directed targeted therapy extended overall survival (OS) in patients with anaplastic thyroid carcinoma (ATC). Findings from the Phase II single center study published today in JAMA Oncology.

24 Oct 2024

myeloMATCH program opens enrollment for acute myeloid leukemia and MDS

Four leading cancer research organizations in the United States and Canada announce the opening of patient enrollment to myeloMATCH, a unique portfolio of clinical trials to test precision medicine treatments for adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).

23 Oct 2024

Trial evaluates monoclonal antibodies for long COVID prevention

The first randomized, placebo-controlled clinical trial evaluating the impact of therapeutic monoclonal antibodies on the risk of developing long COVID was led by researchers at Weill Cornell Medicine.

17 Oct 2024

Efforts to increase diversity in cancer clinical trials fall short

In the U.S., millions of people experience cancer every year but don't have an equal opportunity to access experimental treatments in clinical trials, or to receive treatments that were shown to be effective in patients like them.

15 Oct 2024

Concerns rise over increased industry sponsorship in cancer clinical trials

A growing reliance on industry-sponsored cancer clinical trials in the United States is a reason for concern, say researchers from the UNC Lineberger Comprehensive Cancer Center.

8 Oct 2024

Study reveals sponsorship bias in psychiatric drug trials

Psychiatric drugs are reported to be about 50% more effective in clinical trials funded by the drug's manufacturer than when trials of the same drug are sponsored by other groups, new research shows.

7 Oct 2024

New drug could extend the lives of breast cancer patients

LMU researchers have successfully tested a new drug which can significantly extend the lives of breast cancer patients.

4 Oct 2024

Study highlights benefits and risks of doxy-PEP for STI prevention

Taking a dose of the oral antibiotic doxycycline after a high-risk sexual encounter has dramatically reduced the incidence of sexually transmitted infections (STIs) in places where the strategy is being tried.

4 Oct 2024

Low-dose lithium fails in long COVID trial, but higher doses show potential

A small University at Buffalo clinical trial has found that at low doses, lithium aspartate is ineffective in treating the fatigue and brain fog that is often a persistent feature of long COVID; however, a supplemental dose-finding study found some evidence that higher doses may be effective.

3 Oct 2024

Enhancing the adoption of pragmatic clinical trial results in healthcare systems

A new thought piece led by the Harvard Pilgrim Health Care Institute with collaborators from Duke University and Kaiser Permanente Washington Health Research Institute highlights the challenges facing healthcare researchers and decision makers in the quest to improve population health in a constantly evolving healthcare landscape.

3 Oct 2024

Researchers develop technology to change protein identity in vivo

Researchers at the RIKEN Cluster for Pioneering Research (CPR) have developed technology that can alter, within the body, the recognized identity of proteins. The innovation, published in Nature Communications on October 2, allowed researchers to target mouse tumors with a protein and then transport that protein out of the body.

3 Oct 2024

Dronabinol shows promise in reducing agitation in Alzheimer's patients

In a study led by the Johns Hopkins University School of Medicine and Tufts University School of Medicine, researchers show that a pill form of the drug dronabinol, an FDA-approved synthetic version of marijuana's main ingredient, THC, reduces agitation in patients with Alzheimer's by an average of 30%.

2 Oct 2024

New collaboration aims to break through LGMD treatment barriers

Critical Path Institute (C-Path) today announced the formation of a new task force under its Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP®), dedicated to advancing therapeutic development for limb-girdle muscular dystrophies (LGMDs).

1 Oct 2024

Standard chemoradiation outperforms de-intensified treatments in HPV-associated oropharyngeal cancer

Researchers looking to de-intensify radiation treatments for people with early-stage, HPV-associated oropharyngeal cancer to prevent long-term side effects halted a large, randomized phase II/III trial after patients in the control arm reached a record high, two-year progression-free survival rate of 98%.

30 Sep 2024

Outpatient CAR-T therapy shows promise for treating lymphoma patients

In the largest prospective study to date examining the use of chimeric antigen receptor (CAR)-T therapy in a community setting on an outpatient basis, patients with relapsed or refractory large B-cell lymphoma (LBCL) responded well to treatment with few serious side effects, according to results published today in Blood Advances.

30 Sep 2024

Phase III trials indicate reversible cognitive side effects in brain metastases treatment

A substantial number of patients with brain metastases who experience cognitive side effects following radiation therapy may fully regain cognitive function, according to a pooled analysis of three large, phase III clinical trials.

29 Sep 2024